Oncimmune Holdings PLC is engaged in diagnosing cancer. It is involved in the development, manufacture, and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer. The company's operating segment includes EarlyCDT and ImmunoINSIGHTS. It generates maximum revenue from the EarlyCDT segment.